Effects of dosing intervals on the development of tolerance to high dose transdermal nitroglycerin

The American Journal of Cardiology
E G NabelA P Selwyn

Abstract

To investigate the antiischemic efficacy and development of tolerance to transdermal nitroglycerin, 14 patients with chronic, stable angina pectoris were studied using continuous ambulatory electrocardiographic monitoring. Patients demonstrated initial hemodynamic responsiveness to sublingual nitroglycerin and were titrated to a maximally tolerated dose of 30 to 60 mg/24 hours (52 +/- 5 mg). Two crossover phases were use in a randomized, double-blind, placebo-controlled manner: continuous nitroglycerin therapy (patches containing active drug worn for 24 hours) and intermittent nitroglycerin therapy (12-hour active drug followed by a 12-hour nitrate-free period). There were no differences in frequency or duration of ischemic episodes between the placebo days of each phase. A significant effect in frequency of episodes was observed between placebo and treatment days of continuous therapy (p less than 0.05). Nonsignificant reductions in frequency and duration of ischemic episodes also occurred during intermittent therapy. The major antiischemic effect of transdermal nitroglycerin therapy occurred during the first day of treatment but was lost by 48 hours. Reductions in frequency and duration of ischemic episodes (p less than 0.05)...Continue Reading

References

Sep 1, 1987·Journal of the American College of Cardiology·R LukeR Coxon
Jun 4, 1987·The New England Journal of Medicine·J O ParkerG Moe
Jul 1, 1985·Clinical Pharmacy·S H Curry
Jul 1, 1984·The American Journal of Cardiology·N ReichekM S Sutton
Jul 1, 1984·The American Journal of Cardiology·J O ParkerH L Fung

❮ Previous
Next ❯

Citations

Mar 1, 1996·Cardiovascular Drugs and Therapy·T O Klemsdal, K Gjesdal
Oct 1, 1994·Cardiovascular Drugs and Therapy·H PurcellK Fox
Aug 1, 1994·Cardiovascular Drugs and Therapy·U Thadani, R J Lipicky
Feb 1, 1993·Journal of the American College of Cardiology·E RossettiS L Chierchia
Nov 1, 1992·Postgraduate Medical Journal·S R Maxwell, M J Kendall
Apr 22, 2005·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Peter H Stone
May 1, 1992·Progress in Cardiovascular Diseases·D Mulcahy, K Fox
Jun 15, 1994·International Journal of Cardiology·M Ferratini
Mar 1, 1994·International Journal of Cardiology·F AkhrasG Jackson
Jan 1, 1993·The Journal of International Medical Research·P Löfdahl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.